Phase 3 N=140 Evaluation in the Treatment of Neuropathic Pain Post Breast Surgery
Breast Cancer Patient
Primary: Change in Neuropathic Pain Score at 2 Months (Numeric Rating Scale 0-10) — 4.1; 4.6 units on a scale
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=900 Detection and Classification of Diabetic Retinopathy From Posterior Pole Images With A Deep Learning Model
Diabetic Retinopathy · Diabetic Eye Problems · Diabetic Macular Edema
Primary: Sensitivity(mtmDR) — 90.48; 95.65; 95.19 percentage of true positives
N/A N=22 Scrambler Trial for Pain in NMOSD
Neuromyelitis Optica
Primary: Acceptability as Assessed by the Number of Participants Responding Yes to a Question — 7; 5 Participants
Phase 3 N=44 Brivaracetam to Reduce Neuropathic Pain in Chronic SCI: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial
Spinal Cord Injuries · Neuropathic Pain
Primary: The International Spinal Cord Injury Pain Data Set (ISCIPBDS) (Version 2.0) - Change in Average Worst Neuropathic Pain Intensity — -0.5; -0.5 points
N/A N=80 Lidocaine 5% Patch (Lidoderm) for the Prevention of Acute and Chest Pain Following Robotic Valve Surgery
Perioperative Chest Pain
Primary: Pain Disability Index Score (PDI) at Six Months Following Surgical Procedure — 26; 30; 12; 13 units on a scale — p=0.28
N/A N=10 Effectiveness of rTMS on Pain and Quality of Life in Patients With Cancer Neuropathic Pain. Clinical Trial.
Neuropathic Pain
Primary: Effect of Change of 20 rTMS Sessions on Pain — 5.53; 1.60; 1.97; 3.48 score on a scale
N/A N=39 Effect of Cocoa Supplementation Peripheral and Autonomic Diabetic Neuropathy
Diabetic Neuropathies
Primary: Toronto Clinical Scoring System (TCSS) — -2.63; -1.84; 9.31; 6.89 Score on a scale — p=>0.05
Phase 4 N=144 Treating Phantom Limb Pain Using Continuous Peripheral Nerve Blocks: A Department of Defense Funded Multicenter Study
Phantom Limb Pain
Primary: "Average" Phantom Limb Pain Intensity 4 Weeks Following Initiation of an Ambulatory Continuous Peripheral Nerve Block (as Measured by the Numeric Rating Scale Within the…
Phase 4 N=121 Pregabalin Treatment Of Peripheral Neuropathic Pain Associated With Diabetic Peripheral NeP (DPN), Postherpetic Neuralgia (PHN), HIV-related NeP (HIV), and Chemotherapy Induced NeP
Diabetic Peripheral Neuropathic Pain (DPN) · Postherpetic Neuralgia (PHN) · HIV-related Neuropathic Pain (HIV)
Primary: Change From Baseline to End of Treatment (EOT) in Weekly Mean Pain Score on the Daily Pain Rating Scale (DPRS) — -3.8 scores on scale — p=< 0.0001
Phase 2 N=90 Pain Management in Children and Young Adults With Sickle Cell Disease
Sickle Cell Disease
Primary: Number of Participants With Successful Pain Interventions by Arm Between Presentation and 3 Hours Post Administration of Study Drug — 13; 17; 27; 25 Participants — p=0.227
N/A N=6 tDCS to Lower Neuropathic Pain and Fatigue in People With Multiple Sclerosis
Multiple Sclerosis
Primary: Neuropathic Pain Questionnaire (NPQ) Contains 12 Items. — 21.3; 10.3 Points
Phase 2 N=79 Mechanistic Study of Duloxetine in Breast Cancer Patients With Chronic Pain
Pain
Primary: Change in Patient-reported Worst Pain Between Baseline and 5 Weeks of Treatment With Duloxetine — 6.54; 0.25; 4.06 score on a scale
Phase 3 N=256 Efficacy Study Measuring the Impact of Pregabalin on Peripheral Neuropathic Pain.
Neuropathic Pain
Primary: Neuropathic Pain in Subjects With Peripheral Neuropathic Pain Conditions During the Double-blind Phase — 2.84; 3.62 score on scale — p=0.0018
Phase 2 N=125 Chronic Pain Master Protocol (CPMP): A Study of LY3016859 in Participants With Diabetic Peripheral Neuropathic Pain
Diabetic Peripheral Neuropathic Pain
Primary: Change From Baseline in Average Pain Intensity as Measured by the NRS — -1.98; -1.56 score on a scale
Phase 2 N=155 Chronic Pain Master Protocol (CPMP): A Study of LY3526318 in Participants With Diabetic Peripheral Neuropathic Pain
Diabetic Peripheral Neuropathic Pain
Primary: Change From Baseline in Average Pain Intensity as Measured by the Numeric Rating Scale (NRS) — -1.50; -1.35 score on a scale